Contract Research Organization (CRO): An Important Partner to Biotechnological and Pharmaceutical Companies

  • Santosh Kumar R
  • Paul S
N/ACitations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

With the ever increasing Research and Development cost for the pharmaceutical industries, the cost of bringing a drug to market was increasing drastically. The funds for drug development was drying up and thus to maintain a healthy profit margin , the pharmaceutical companies have adopted to frame out research and development (R&D) to Contract Research Organizations (CRO’s). The CRO’s have become an important partner to biotechnological and pharmaceutical companies, in the development of new compounds and at the same time in drug registration also it has extended its hands. Out of 20, 19 pharmaceutical companies have invested in emerging markets like China, India, Russia and Latin America since clinical research is accessible to these markets due to adoption of ICH and GCPs guidelines. The traditional nature of CRO’s have changed and they will develop into a formidable industry in near future.

Cite

CITATION STYLE

APA

Santosh Kumar, R., & Paul, S. (2019). Contract Research Organization (CRO): An Important Partner to Biotechnological and Pharmaceutical Companies. Journal of Drug Delivery and Therapeutics, 9(4-A), 759–761. https://doi.org/10.22270/jddt.v9i4-a.3481

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free